The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19

Antimicrob Agents Chemother. 2020 Jul 22;64(8):e01127-20. doi: 10.1128/AAC.01127-20. Print 2020 Jul 22.
No abstract available

Keywords: COVID-19; consumption; hydroxychloroquine; lopinavir–ritonavir; treatment.

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Azithromycin / therapeutic use
  • Betacoronavirus / drug effects*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Deception
  • Drug Combinations
  • France
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Lopinavir / therapeutic use
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Scholarly Communication*

Substances

  • Antiviral Agents
  • Drug Combinations
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Azithromycin
  • Ritonavir